PH12022552483A1 - Therapeutic musk antibodies - Google Patents

Therapeutic musk antibodies

Info

Publication number
PH12022552483A1
PH12022552483A1 PH1/2022/552483A PH12022552483A PH12022552483A1 PH 12022552483 A1 PH12022552483 A1 PH 12022552483A1 PH 12022552483 A PH12022552483 A PH 12022552483A PH 12022552483 A1 PH12022552483 A1 PH 12022552483A1
Authority
PH
Philippines
Prior art keywords
musk
therapeutic
antibodies
present
musk antibodies
Prior art date
Application number
PH1/2022/552483A
Other languages
English (en)
Inventor
Christophe Blanchetot
Steven J Burden
Akiko Koide
Shohei Koide
Nadia Leloup
Julien Oury
Karen Silence
Roeland Vanhauwaert
Original Assignee
argenx BV
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV, Univ New York filed Critical argenx BV
Publication of PH12022552483A1 publication Critical patent/PH12022552483A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2022/552483A 2020-04-17 2021-04-16 Therapeutic musk antibodies PH12022552483A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063011986P 2020-04-17 2020-04-17
US202063038633P 2020-06-12 2020-06-12
US202063112375P 2020-11-11 2020-11-11
PCT/US2021/027801 WO2021212053A2 (en) 2020-04-17 2021-04-16 Therapeutic musk antibodies

Publications (1)

Publication Number Publication Date
PH12022552483A1 true PH12022552483A1 (en) 2024-02-05

Family

ID=75850676

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/552483A PH12022552483A1 (en) 2020-04-17 2021-04-16 Therapeutic musk antibodies

Country Status (12)

Country Link
US (2) US11492401B2 (https=)
EP (1) EP4136115A2 (https=)
JP (2) JP7772715B2 (https=)
KR (1) KR20230028217A (https=)
CN (1) CN115843268A (https=)
AU (1) AU2021256049A1 (https=)
BR (1) BR112022021065A2 (https=)
CA (1) CA3175597A1 (https=)
IL (1) IL297295A (https=)
MX (1) MX2022011856A (https=)
PH (1) PH12022552483A1 (https=)
WO (1) WO2021212053A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147489A2 (en) * 2022-01-28 2023-08-03 argenx BV Anti-musk antibodies for use in treating neuromuscular disorders
WO2023218099A1 (en) * 2022-05-13 2023-11-16 argenx BV In utero treatment of a fetus having genetic disease/neuromuscular disease
AU2024271522A1 (en) * 2023-05-15 2025-11-20 argenx BV Antibodies for use in agrin-deficient disorders
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6737249B1 (en) 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US6624819B1 (en) 2000-05-01 2003-09-23 Broadcom Corporation Method and system for providing a flexible and efficient processor for use in a graphics processing system
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2453822C (en) 2001-08-03 2011-02-22 Tyco Healthcare Group Lp Tissue marking apparatus and method
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
JP2011207769A (ja) 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
WO2013074636A1 (en) 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
US9574015B2 (en) 2013-09-13 2017-02-21 New York University Methods for treating muscle specific receptor kinase (MuSK) myasthenia gravis with the Ig1 domain of MuSK

Also Published As

Publication number Publication date
AU2021256049A1 (en) 2022-11-03
BR112022021065A2 (pt) 2023-02-23
JP2026056615A (ja) 2026-04-01
IL297295A (en) 2022-12-01
JP7772715B2 (ja) 2025-11-18
US11492401B2 (en) 2022-11-08
US20220259304A1 (en) 2022-08-18
WO2021212053A3 (en) 2021-11-18
WO2021212053A8 (en) 2022-09-29
MX2022011856A (es) 2023-02-23
CN115843268A (zh) 2023-03-24
WO2021212053A2 (en) 2021-10-21
JP2023522212A (ja) 2023-05-29
CA3175597A1 (en) 2021-10-21
KR20230028217A (ko) 2023-02-28
US20230151091A1 (en) 2023-05-18
EP4136115A2 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
PH12022552483A1 (en) Therapeutic musk antibodies
MX2021006971A (es) Anticuerpos anti-muc16 x anti-cd28 biespecificos y usos de estos.
MX2020013804A (es) Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
EA201890368A1 (ru) Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение
PH12022550509A1 (en) Anti-cd73 antibodies
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
SA523442921B1 (ar) جزيئات ربط علاجية
EA202091747A1 (ru) Составы антитела b7-h4
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
BR112022016232A2 (pt) Proteínas biespecíficas anti-her2 manipuladas
ZA202302392B (en) Antibodies against ilt2 and use thereof
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
MX2023004020A (es) Anticuerpos anti-ngf y métodos para su uso.
ZA202212133B (en) Anti-cd200r1 antibodies and methods of use thereof
ZA202208222B (en) Anti-acvr1 antibodies and uses thereof
ZA202110285B (en) Antibodies and methods of use
MX2022014224A (es) Construcciones de anticuerpos de dominio individual neutralizantes contra sars-cov2.
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
EA202191677A1 (ru) Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения